77. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113-130. 78. U.S. Food and Drug Administration. Methadone use for pain control may result in death and life-threatening changes in breathing and heart beat. http://www.methadone.org/downloads/ documents/fda_comsumer_updates_2006_ methadone_pain_control_death_changes_ breathing_heart_beat_nov_.pdf. Published November 2006. Accessed 3-23-18. 79. Chou R, Cruciani RA, Fiellin DA, et al. Methadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. J Pain. 2014;15(4):321- 337. 80. U.S. Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Abuse- Deterrent Opioids — Evaluation and Labeling: Guidance for Industry. http://www.fda.gov/Drugs/ GuidanceComplianceRegulatoryInformation/ Guidances/default.htm. Published April 2015. Accessed. 81. Litman RS, Pagán OH, Cicero TJ. Abuse- deterrent Opioid Formulations. Anesthesiology. 2018;128(5):1015-1026. 82. National Institute on Drug Abuse, National Institutes of Health, U.S. Department of Health and Human Services. Dramatic Increases in Maternal Opioid Use and Neonatal Abstinence Syndrome. https://www.drugabuse.gov/drug- topics/trends-statistics/infographics/dramatic- increases-in-maternal-opioid-use-neonatal- abstinence-syndrome. Published January 22, 2019. Accessed April 15, 2021. 83. U.S. Food and Drug Administration. Neonatal opioid withdrawal syndrome and medication- assisted treatment with methadone and buprenorphine. https://www.fda.gov/Drugs/ DrugSafety/ucm503630.htm. Published May 26, 2016. Accessed 4-10-18. 84. Tennessee Department of Health. Tennessee Chronic Pain Guidelines: Clinical Practice Guidelines for Outpatient Management of Chronic Non-Malignant Pain. 2017. 85. Washington State Agency Medical Directors’ Group. Interagency Guideline on Prescribing Opioids for Pain, 3rd ed. 2015. 86. Schechter NL, Walco GA. The Potential Impact on Children of the CDC Guideline for Prescribing Opioids for Chronic Pain: Above All, Do No Harm. JAMA Pediatr. 2016;170(5):425-426. 87. Conway BR, Fogarty DG, Nelson WE, Doherty CC. Opiate toxicity in patients with renal failure. BMJ. 2006;332(7537):345-346. 88. Brousseau DC, Panepinto JA, Nimmer M, Hoffmann RG. The number of people with sickle- cell disease in the United States: national and state estimates. Am J Hematol. 2010;85(1):77- 78. 89. Bonhomme J, Shim RS, Gooden R, Tyus D, Rust G. Opioid addiction and abuse in primary care practice: a comparison of methadone and buprenorphine as treatment options. J Natl Med Assoc. 2012;104(7-8):342-350.
90. Gallagher RM. Advancing the Pain Agenda in the Veteran Population. Anesthesiol Clin. 2016;34(2):357-378. 91. Kapur BM, Lala PK, Shaw JL. Pharmacogenetics of chronic pain management. Clin Biochem. 2014;47(13-14):1169-1187. 92. American Psychiatric Association. Opioid Use Disorder Diagnostic Criteria. Diagnostic and Statistical Manual of Mental Disorders, 5th Edition: DSM-5. 2013. 93. Substance Abuse and Mental Health Services Administration. (2020). Key substance use and mental health indicators in the United States: Results from the 2019 National Survey on Drug Use and Health (HHS Publication No. PEP20- 07-01-001, NSDUH Series H-55). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. Retrieved from https:// www.samhsa.gov/data/. Accessed. 94. Bicket MC, Long JJ, Pronovost PJ, Alexander GC, Wu CL. Prescription opioid analgesics commonly unused after surgery: a systematic review. JAMA Surg. 2017;152(11):1066-1071. 95. Hatten BW, Cantrill SV, Dubin JS, et al. Clinical Policy: Critical Issues Related to Opioids in Adult Patients Presenting to the Emergency Department. Ann Emerg Med. 2020;76(3):e13-e39. 96. Kellezi B, Coupland C, Morriss R, et al. The impact of psychological factors on recovery from injury: a multicentre cohort study. Soc Psychiatry Psychiatr Epidemiol. 2017;52(7):855-866. 97. Dindo L, Zimmerman MB, Hadlandsmyth K, et al. Acceptance and Commitment Therapy for Prevention of Chronic Postsurgical Pain and Opioid Use in At-Risk Veterans: A Pilot Randomized Controlled Study. J Pain. 2018;19(10):1211-1221. 98. Darnall B. Applying Psychological Science for Pain Relief and Opioid Reduction. Keynote Speaker presented at the: American Psychological Association Annual National Convention 2018; San Francisco, CA. 99. Pauli J, Starkweather A, Robins JL. Screening Tools to Predict the Development of Chronic Low Back Pain: An Integrative Review of the Literature. Pain Med. 2019;20(9):1651-1677. 100. Paice JA, Ferrell B. The management of cancer pain. CA Cancer J Clin. 2011;61(3):157-182. 101. Nelson AE, Allen KD, Golightly YM, Goode AP, Jordan JM. A systematic review of recommendations and guidelines for the management of osteoarthritis: The chronic osteoarthritis management initiative of the U.S. bone and joint initiative. Semin Arthritis Rheum. 2014;43(6):701-712. 102. Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form- 36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res (Hoboken). 2011;63(S11):S240-S252.
103. Tan G, Jensen MP, Thornby JI, Shanti BF. Validation of the Brief Pain Inventory for chronic nonmalignant pain. J Pain. 2004;5(2):133-137. 104. Stanhope J. Brief Pain Inventory review. Occup Med (Lond). 2016;66(6):496-497. 105. Krebs EE, Lorenz KA, Bair MJ, et al. Development and initial validation of the PEG, a three-item scale assessing pain intensity and interference. J Gen Intern Med. 2009;24(6):733-738. 106. Junghaenel DU, Broderick JE. Validation of the MPI patient profiles by partners and healthcare providers. Pain. 2009;144(1-2):130-138. 107. 107. Kerns RD, Turk DC, Rudy TE. The West Haven-Yale Multidimensional Pain Inventory (WHYMPI). Pain. 1985;23(4):345-356. 108. Polomano RC, Galloway KT, Kent ML, et al. Psychometric Testing of the Defense and Veterans Pain Rating Scale (DVPRS): A New Pain Scale for Military Population. Pain Med. 2016;17(8):1505-1519. 109. Kroenke K, Spitzer RL, Williams JB. The Patient Health Questionnaire-2: validity of a two-item depression screener. Med Care. 2003;41(11):1284-1292. 110. Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: Validity of a Brief Depression Severity Measure. J Gen Intern Med. 2001;16(9):606-613. 111. Wang YP, Gorenstein C. Psychometric properties of the Beck Depression Inventory- II: a comprehensive review. Rev Bras Psiquiatr. 2013;35(4):416-431. 112. Geissner E, Huetteroth A. [Beck Anxiety Inventory German Version - A Reliable, Valid, Patientfriendly Instrument for Measuring Clinical Anxiety]. Psychother Psychosom Med Psychol. 2018. 113. Kroenke K, Spitzer RL, Williams JB, Lowe B. The Patient Health Questionnaire Somatic, Anxiety, and Depressive Symptom Scales: a systematic review. Gen Hosp Psychiatry. 2010;32(4):345- 359. 114. Sapra A, Bhandari P, Sharma S, Chanpura T, Lopp L. Using Generalized Anxiety Disorder-2 (GAD-2) and GAD-7 in a Primary Care Setting. Cureus. 2020;12(5):e8224-e8224. 115. Carriere J, Darnall B, Kao M, Mackey S. (489) An examination of the roles of perceived injustice and pain acceptance on pain interference and pain intensity in patients with chronic pain: A Collaborative Health Outcomes Information Registry (CHOIR) Study. J Pain. 2016;17(4s):S97. 116. Esposito DB, Cepeda MS, Lyons JG, Yin R, Lanes S, Members of the Opioid Post-Marketing Consortium Observational Studies Working G. Medical record-based ascertainment of behaviors suggestive of opioid misuse, diversion, abuse, and/or addiction among individuals showing evidence of doctor/pharmacy shopping. J Pain Res. 2019;12:2291-2303. 117. Fleming MF, Balousek SL, Klessig CL, Mundt MP, Brown DD. Substance use disorders in a primary care sample receiving daily opioid therapy. J Pain. 2007;8(7):573-582. 118. Webster LR. Risk factors for opioid-use disorder and overdose. Anesth Analg. 2017;125(5):1741- 1748.
69
Powered by FlippingBook